The 24-month randomized trial of 365 adults aged 55–80 found that omega-3 supplementation increased DHA levels in cerebrospinal fluid after six months but produced no improvement in memory, overall cognition, or brain-imaging measures over two years. The results highlight that a measurable biological change does not necessarily translate into clinical benefit. Limitations include the specific population, dose/formulation tested, and unanswered questions about dietary sources and earlier or different supplementation strategies.
Omega-3 Reality Check: Brain DHA Rose — But Memory and Cognition Did Not Improve
Fish Oil
A large 24-month randomized clinical trial produced a clear, if unexpected, result: omega-3 supplementation raised DHA levels linked to the brain but produced no measurable improvements in memory, overall cognition, or brain-imaging markers in the study group.
The study enrolled 365 cognitively unimpaired adults aged 55–80 who reported low dietary DHA intake and had at least one risk factor for dementia. Participants were randomized to receive omega-3 supplements or placebo and were followed for two years to test whether supplementation would change cognitive trajectories and brain-related measures.
Biological Uptake: The Supplement Worked — In the Body
At the biological level, the intervention succeeded. After six months, those receiving omega-3 supplements showed increased docosahexaenoic acid (DHA) concentrations in cerebrospinal fluid, indicating the supplement reached an environment closely connected with the brain.
No Cognitive Or Imaging Benefit
Despite that clear biochemical change, the primary outcomes showed no cognitive benefit. Over the full 24 months, participants in the omega-3 group did not improve on tests of memory or broader cognitive performance compared with the placebo group. Researchers also found no treatment effect on brain-imaging outcomes, including hippocampal volume, cortical thickness, and a range of structural and functional MRI measures.
Image Credit:Gpkp,CC BY-SA 4.0, via Wikimedia Commons
Hussein Yassine: "Even when we saw high levels of omega 3 in the brains of the treatment group, it did not improve cognition."
What This Means — And What It Doesn’t
The trial underscores an important distinction: a supplement can produce a measurable biological response without producing a measurable change in everyday brain function. This finding does not remove DHA's biological importance, but it does temper expectations that raising a biomarker will automatically translate into preserved or improved cognition for older adults with the specific characteristics studied.
Limitations matter. The trial tested a particular supplement regimen in older adults who were cognitively normal at baseline but had low dietary DHA and at least one dementia risk factor. It does not answer whether dietary sources of omega-3, different doses or formulations, earlier or longer-term supplementation, or different populations might yield different outcomes.
Broader Context
Observational studies have sometimes linked higher omega-3 intake or blood levels to better cognitive outcomes, but randomized trials have been inconsistent. Controlled interventions like this one are critical for testing causation rather than correlation. For consumers and clinicians, the takeaway is that biomarker changes are encouraging but not sufficient evidence that a pill will meaningfully preserve memory or cognitive function.
As researchers continue to study ways to support brain health, this trial highlights the need for rigorously designed studies that test whether common assumptions about supplements actually produce real-world benefits.
Image credit: Gpkp, CC BY-SA 4.0, via Wikimedia Commons
Help us improve.
